VIP Peptide Guide 2026: Aviptadil Evidence and Dosing

VIP Peptide Guide 2026: Aviptadil Evidence and Dosing
Educational use only. This article is informational and does not constitute medical advice. Peptide dosing decisions should be made in consultation with a licensed physician familiar with your medical history. Always verify any dose with your prescribing physician before drawing or administering. Some peptides discussed are not FDA-approved for human use; legal and regulatory status varies by jurisdiction.

Quick Answer

Vasoactive intestinal peptide (VIP) is a 28-amino-acid neuropeptide first isolated from the porcine gut by Said and Mutt in 1970 (PMID 5450698). It binds the VPAC1 and VPAC2 G-protein coupled receptors, raises intracellular cyclic AMP, and produces vasodilation, smooth muscle relaxation, and a well-characterized anti-inflammatory profile that includes induction of regulatory T cells and suppression of TNF-alpha, IL-6, and IL-12. The synthetic drug form is called aviptadil (brand names RLF-100 and ZYESAMI). Aviptadil is not FDA-approved for any indication in the United States, but it holds three FDA orphan designations (ARDS 2001, pulmonary arterial hypertension 2005, sarcoidosis 2021-08-03) and was the subject of two large COVID-19 ARDS Phase 3 trials. The independent NIH-sponsored TESICO trial was stopped for futility in May 2022 and showed no mortality benefit with a clear excess of hypotension (58 percent vs 41 percent) and diarrhea (40 percent vs 11 percent) compared to placebo (PMID 37348524). A separate clinical community uses compounded intranasal aviptadil at 50 mcg per spray four times daily (200 mcg per day) as the final step of the Ritchie Shoemaker chronic inflammatory response syndrome protocol, supported by a single open-label case series of 20 patients published in 2013 in a non-PubMed-indexed journal. The two literatures barely overlap; both audiences search for “VIP peptide” but they are reading different evidence.

Table of Contents


VIP is one of the most extensively studied neuropeptides in biology. It is also one of the most therapeutically slippery: a molecule with a clear physiologic role, dense receptor biology, and decades of preclinical promise, but a clinical-trial record where most signals have not translated. This guide walks through what is established, what is plausible, and what remains community framing rather than evidence.

What VIP Is

VIP is a 28-amino-acid linear peptide with the sequence His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH2. The C-terminal asparagine is amidated; the amide is required for full receptor binding, which is why the free acid form circulates as a degradation product rather than an active form. Average molecular weight is 3326.8 daltons (PubChem CID 53314964). The CAS number is 37221-79-7 and the UniProt accession for the full 170-amino-acid prepro-VIP precursor is P01282.

VIP belongs to the glucagon and secretin family of peptide hormones. Its closest relative is PACAP (pituitary adenylate cyclase-activating polypeptide), with roughly 67 percent sequence identity across their N-terminal overlap. VIP and PACAP share the VPAC1 and VPAC2 receptors with comparable affinity. PACAP also binds PAC1 with about a thousand-fold higher affinity than VIP, which is why PACAP-specific effects such as trigeminal migraine provocation are not fully replicated by VIP.

The gene is on chromosome 6q25.2 and encodes a 170-amino-acid precursor that yields not only VIP but also the related peptide PHM-27 (peptide histidine methionine, which has its own weaker VPAC activity in humans). Some older immunohistochemistry studies that report “VIP-immunoreactivity” are actually detecting both VIP and PHM. This matters when reading historical literature on tissue distribution.

VIP is endogenously expressed in the enteric nervous system, the suprachiasmatic nucleus (the central circadian pacemaker), cortex, hippocampus, hypothalamus, parasympathetic ganglia, pelvic nerves, airway smooth muscle innervation, and across the immune system on lymphocytes, macrophages, and mast cells. This wide distribution is the basis for the very different therapeutic hypotheses that have been tested: pulmonary delivery for lung disease, intracavernosal for erectile function, intranasal for nasal and central effects, and intravenous for systemic inflammation.

The synthetic drug form is called aviptadil. RLF-100 (Relief Therapeutics) and ZYESAMI (NRx Pharmaceuticals) are sponsor brand names for the same molecule. Invicorp, a UK-licensed product combining aviptadil 25 mcg with phentolamine 2 mg for intracavernosal injection in erectile dysfunction, is the only marketed product anywhere that contains aviptadil for a non-investigational indication. It has been available in the United Kingdom since October 2000.

VIP Identity Snapshot

AttributeValue
Peptide length28 amino acids (linear, C-terminal amidated)
SequenceHis-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH2
Molecular formulaC147H237N43O43S
Average molecular weight3326.8 g/mol
CAS Registry Number37221-79-7
PubChem CID53314964
UniProtP01282 (170-aa prepro-VIP precursor)
Gene / locusVIP, chromosome 6q25.2
FamilyGlucagon / secretin superfamily (closest relative: PACAP, ~67% N-terminal identity)
ReceptorsVPAC1 (VIPR1, 3p22.1), VPAC2 (VIPR2, 7q36.3); weak PAC1
Primary signalingGalpha-s -> adenylyl cyclase -> cAMP -> PKA
Plasma half-life (native VIP)~1-2 minutes
Primary degrading enzymesDPP-IV, FAP, neprilysin
Synthetic drug form (INN)Aviptadil
Sponsor brand namesRLF-100 (Relief Therapeutics), ZYESAMI (NRx Pharmaceuticals)
Only marketed product anywhereInvicorp (aviptadil 25 mcg + phentolamine 2 mg, UK, intracavernosal, ED), since October 2000
US FDA approval statusNot approved for any indication; three orphan designations (ARDS 2001, PAH 2005, sarcoidosis 2021-08-03)

Mechanism of Action

Receptors and Primary Signaling

VIP binds three Class B1 secretin-family G-protein coupled receptors. VPAC1 is encoded by VIPR1 on chromosome 3p22.1 and is the predominant lymphoid receptor; it is also abundantly expressed in lung, liver, and intestine. VPAC2 is encoded by VIPR2 on chromosome 7q36.3 and predominates on smooth muscle, mast cells, and in the suprachiasmatic nucleus. PAC1 (ADCYAP1R1) binds VIP only weakly and is the PACAP-selective receptor.

Both VPAC1 and VPAC2 couple primarily through G-alpha-s to adenylyl cyclase, generating cyclic AMP and activating protein kinase A. This is the canonical and best-characterized VIP pathway. Cyclic AMP is the proximal second messenger for essentially all of VIP’s vasodilator, smooth muscle relaxant, and anti-inflammatory effects. Secondary pathways include phospholipase C with IP3-mediated calcium release at higher VIP concentrations, MAPK and ERK1/2 activation supporting neurotrophic effects, and PI3K-Akt for neuronal survival signaling. Most of the secondary-pathway evidence is stronger for PACAP than for VIP directly, with VIP findings often inferred by analogy through the shared VPAC receptors.

Anti-Inflammatory Profile

VIP is unusual among neuropeptides in having a mechanistically dissected anti-inflammatory profile. The canonical reviews are Delgado and Ganea, Amino Acids 2013 (PMID 22139413), and Pozo and Delgado, FASEB Journal 2004 (PMID 15333575). Established effects across the Delgado, Ganea, Gomariz, and Pozo body of work include the following:

A Th1 to Th2 cytokine shift, with suppression of IL-12 and IFN-gamma and promotion of IL-4, IL-5, and IL-10. Induction of regulatory T cells, specifically the CD4+CD25+Foxp3+ subset, observed in both mouse models and in human peripheral blood after inhaled VIP in sarcoidosis (Prasse 2010). Suppression of pro-inflammatory cytokines including TNF-alpha, IL-6, IL-1-beta, IL-12, and IFN-gamma in macrophages and dendritic cells. Induction of IL-10, which is the major anti-inflammatory output of VIP signaling. Suppression of the NF-kB pathway in monocytes and macrophages. A tolerogenic shift in dendritic cells, where VIP-conditioned DCs preferentially induce regulatory T cells. Mast cell stabilization through VPAC2, relevant because of the overlap between chronic inflammatory response syndrome (CIRS) and mast cell activation syndrome (MCAS) in functional medicine practice.

This is a coherent immunoregulatory profile, and it is what drove the therapeutic hypotheses that VIP would be useful in autoimmune disease, sepsis, sarcoidosis, and inflammatory respiratory failure. The clinical-trial record below is the test of whether that biology translates.

Vasodilation

VIP is 50 to 100-fold more potent as a vasodilator than acetylcholine in some preparations (Henning and Sawmiller, Cardiovascular Research 2001;49(1):27-37). The mechanism is straightforward: cAMP elevation in vascular smooth muscle reduces intracellular calcium and dephosphorylates myosin light chain, producing smooth muscle relaxation. UniProt P01282 summarizes the cardiovascular profile: “causes vasodilation, lowers arterial blood pressure, stimulates myocardial contractility, increases glycogenolysis, and relaxes the smooth muscle of trachea, stomach and gall bladder.” The clinical relevance of this potency is the dose-related hypotension and tachycardia documented in the COVID-19 IV aviptadil trials.

Circadian Role

VIP-expressing neurons in the suprachiasmatic nucleus are central to mammalian circadian synchronization. Knockout of the VIP gene in mice disrupts circadian behavior and SCN neuron synchronization. The canonical reference is Aton et al., Nature Neuroscience 2005;8(4):476-83 (PMID 15750589). This role is relevant for the broader framing of VIP as a transmitter rather than a hormone, but does not directly inform any current therapeutic application.

Pharmacokinetics and Degradation

Native VIP has a plasma half-life on the order of one to two minutes, which is the central pharmacokinetic constraint on every therapeutic delivery strategy ever developed for it. The primary degrading enzyme is dipeptidyl peptidase IV (DPP-IV), which cleaves at position 2 (serine), removing the histidine-serine N-terminus and abolishing receptor binding. The DPP-IV interaction is formally annotated in UniProt P01282. Fibroblast activation protein alpha (FAP) is the other major degrading enzyme. Neutral endopeptidase (neprilysin) is widely cited as also contributing to VIP degradation but is less formally documented in the protein interaction databases.

This rapid systemic clearance is why IV bolus VIP disappears in minutes and why every successful therapeutic application has used either continuous IV infusion (aviptadil for ARDS and PAH), inhaled or nebulized delivery (direct to airway and alveolar target tissue), or intranasal delivery (which bypasses much of the portal-system DPP-IV). Subcutaneous VIP works but with rapid systemic clearance comparable to IV bolus.

A Note on Aviptadil vs Research-Peptide VIP

These are the same molecule chemically, but they reach the user through very different supply chains and with very different regulatory framing. Aviptadil is the synthetic drug-grade INN-designated form used in NRx and Relief Therapeutics clinical trials and in the Invicorp combination product. Research-peptide VIP is the lyophilized chemical sold by peptide retailers with “for research use only” disclaimers. Compounded VIP from a 503A pharmacy is regulated separately. The compounding pharmacy preparation used in the Shoemaker CIRS protocol is sometimes called aviptadil on the label and sometimes called VIP; both labels refer to the same synthetic 28-amino-acid molecule. The distinction that matters is not the name on the vial but the regulatory pathway by which it reached the patient.

Preclinical Evidence

The preclinical VIP literature is extensive. A few touchstones illustrate what was promising at the bench and what then did not always translate.

In a DBA/1 mouse collagen-induced arthritis model, intraperitoneal VIP reduced joint inflammation, articular cartilage and bone erosion, and pro-inflammatory cytokine production while promoting IL-10 and TGF-beta (Delgado et al., Nature Medicine 2001;7(3):563-8, PMID 11329057). In a mouse LPS endotoxemia model, VIP protected against lethal endotoxic shock by suppressing TNF-alpha and IL-6 (Martinez et al., PNAS 2002, PMID 11792830). In NOD mice modeling Sjogren’s syndrome, adeno-associated viral delivery of human VIP to submandibular glands improved salivary flow and reduced glandular inflammation (Lodde et al., Annals of the Rheumatic Diseases 2006;65(2):195-200, PMID 15975969). Male VIP-knockout mice developed spontaneous moderate pulmonary arterial hypertension with right ventricular hypertrophy, establishing VIP as endogenously protective against pulmonary vascular remodeling (Said et al., Circulation 2007;115(10):1180-7, PMID 17309917).

Beyond these, VIP has a sizable literature in mast cell stabilization and in neurotrophic models including Alzheimer’s beta-amyloid toxicity, Parkinson’s MPTP and 6-OHDA models, ischemic stroke, and spinal cord injury. The Brenneman and Gozes laboratories generated much of this work.

The honest read of the preclinical body is that it is rich and mechanistically coherent. The honest read of the translation from animal models to human therapeutic benefit is that it has been poor across virtually all indications. The pulmonary hypertension signal looked strong; the human trials produced modest, transient effects. The sepsis signal looked strong; no successful human translation. The sarcoidosis signal was promising; no Phase 3 has been completed. The COVID-19 ARDS hypothesis was biologically plausible; TESICO failed. Cite the preclinical work for mechanism, not for clinical efficacy.

The Mold Biotoxin / CIRS Preclinical Hypothesis

The Shoemaker CIRS framework proposes that exposure to mold mycotoxins and related biotoxins in genetically susceptible individuals (those with certain HLA-DR-DQ haplotypes) leads to failed innate-immune clearance, chronic activation of the innate immune system, and derangement of complement (C3a, C4a), cytokines (TGF-beta-1, IL-1-beta), VEGF, MMP-9, and several hypothalamic-pituitary hormones. VIP’s documented suppression of TNF-alpha, induction of regulatory T cells, and mast cell stabilizing effects make it a mechanistically reasonable candidate for an immunoregulatory intervention if that framework is accepted.

What is important to distinguish: VIP’s general anti-inflammatory mechanism is well established. The specific causal chain proposed by the CIRS framework, from inhaled mycotoxins to multisystem illness corrected by intranasal VIP, is not. The use is hypothesis-driven, not RCT-validated. Readers searching from a functional-medicine starting point should understand both halves of that sentence.

Human Clinical Evidence

Clinical Trial Inventory at a Glance

The table below is the complete inventory of the Phase 2 and Phase 3 human-subject trials that anchor the VIP / aviptadil evidence base. Lead with TESICO when characterizing the COVID-19 record: it was the larger, independent, NIH-sponsored trial, and it was stopped for futility with confirmed excess toxicity. The Youssef sponsor-led trial had positive secondary signals but missed its primary endpoint.

Trial / ReferenceIndicationDesign / nDose & RoutePrimary Result
TESICO / ACTIV-3b – Brown 2023, NCT04843761, PMID 37348524COVID-19 ARDSPhase 3 RCT, double-blind, placebo-controlled; n=471 in aviptadil substudyIV aviptadil 50/100/150 pmol/kg/hr x 12h x 3 daysNegative. DSMB stopped for futility 2022-05-25. Day-90 mortality 38% vs 36% placebo (HR 1.04, p=0.78). Hypotension 58% vs 41% (p<0.001); diarrhea 40% vs 11% (p<0.001).
Youssef 2022 – NCT04311697, PMID 36044317COVID-19 critical respiratory failurePhase 2/3 RCT, sponsor-led (NRx); n=196 (originally targeted 296)IV aviptadil 50/100/150 pmol/kg/hr x 12h x 3 daysPrimary endpoint not met (OR 1.6, 95% CI 0.86-3.11 for alive + free of respiratory failure at day 60). Secondary 60-day survival OR 2.0, p=0.035.
Leuchte 2008 – PMID 18978135 (corrected per audit; originally cited as 18579541)Pulmonary hypertension (mixed etiology)Single-dose hemodynamic study during right heart cath; n=20Single 100 mcg inhaled aviptadilSmall, transient, selective pulmonary vasodilation; 6/20 had >20% PVR reduction. Smaller / shorter than Petkov 2003 had suggested.
Petkov 2003 – PMID 12727925Primary pulmonary hypertension (idiopathic PAH)Open-label single-arm; n=850 mcg per inhalation, 4x/day = 200 mcg/day chronic (12 and 24 weeks)Significant improvement in 6-minute walk test (p<0.01); reduced PVR; improved NYHA class. No subsequent Phase 3.
Prasse 2010 – PMID 20442436Pulmonary sarcoidosisOpen-label Phase II; n=20, 4 weeksNebulized VIP (commonly cited as 100 mcg QID)Well tolerated; reduced TNF-alpha in bronchoalveolar lavage; expanded CD4+CD25+Foxp3+ Tregs in peripheral blood. No follow-up RCT.
Pellesi 2021 – PMID 34357396Migraine provocation (not treatment)Randomized, double-blind, placebo-controlled crossover; n=21IV VIP infusionAdverse-effect trial: 15/21 (71%) developed migraine after VIP vs 1/21 (5%) after placebo (p<0.001). Establishes VIP as a recognized headache trigger.

COVID-19 ARDS: The Largest Dataset

The largest body of human clinical evidence for aviptadil is in COVID-19 associated acute respiratory distress syndrome. Two Phase 3-scale trials and several smaller ones tested it. The result, taken together, was negative.

NCT04311697 was the NRx-sponsored Phase 2/3 trial of IV aviptadil in COVID-19 critical respiratory failure. The protocol used three 12-hour IV infusions on three successive days at escalating doses of 50, 100, and 150 picomoles per kilogram per hour. At a 70 kg body weight, that corresponds to approximately 12, 23, and 35 micrograms per hour at the three steps. (The figure “67 mcg/hour continuous” that appears in some secondary sources does not match the published trial protocol and should not be cited.) Two hundred and ninety-six critically ill patients were randomized 2:1. The primary endpoint of being alive and free of respiratory failure at day 60 was not met (odds ratio 1.6, 95 percent confidence interval 0.86 to 3.11). A sponsor-emphasized secondary endpoint of 60-day survival showed odds ratio 2.0, 95 percent confidence interval 1.1 to 3.9, p = 0.035 (Youssef et al., Critical Care Medicine 2022;50(11):1545-1554, PMID 36044317).

NCT04843761, the TESICO trial, was the independent NIH ACTIV consortium Phase 3 master protocol comparing aviptadil to remdesivir, both, or neither in COVID-19 ARDS. Four hundred seventy-one patients were enrolled in the aviptadil substudy. The Data Safety Monitoring Board stopped the aviptadil arm for futility on May 25, 2022 with conditional power of 12.4 percent. Day 90 mortality was 38 percent in the aviptadil arm (86 deaths) versus 36 percent in the placebo arm (83 deaths), hazard ratio 1.04 (0.77 to 1.41), p = 0.78. No mortality benefit. The primary safety composite was numerically worse with aviptadil (63 percent versus 56 percent, odds ratio 1.40, 95 percent confidence interval 0.94 to 2.08, p = 0.10). Several individual adverse events were significantly more common on aviptadil: diarrhea 39.8 percent versus 11.3 percent (p less than 0.001), hypotension 58.4 percent versus 41.3 percent (p less than 0.001), tachycardia 9.5 percent versus 4.8 percent (p = 0.049), and infusion paused due to adverse event 30.7 percent versus 15.2 percent (Brown et al., Lancet Respiratory Medicine 2023;11(9):791-803, PMID 37348524).

The accompanying Lancet editorial (PMID 37348523) was titled “A negative trial for vasoactive intestinal peptide in COVID-19-associated acute hypoxaemic respiratory failure.”

The honest framing of this dataset is that lead with TESICO, not Youssef. TESICO was the independent NIH-sponsored trial. It was larger. It was stopped for futility. It showed no mortality benefit. And it confirmed real, clinically meaningful elevations in acute toxicity (diarrhea at roughly 3.5x placebo and hypotension at roughly 1.4x placebo). The Youssef trial had positive secondary signals but missed its primary endpoint and was sponsor-led. Aviptadil did not work for COVID-19 ARDS, and it caused predictable on-drug vasodilator and gastrointestinal toxicity at the doses needed for systemic exposure.

The FDA declined the first aviptadil emergency use authorization application on November 4, 2021 and the second narrower remdesivir-refractory application in July 2022.

Pulmonary Arterial Hypertension: Leuchte 2008

The Leuchte study was a single-dose inhaled aviptadil hemodynamic assessment performed during right heart catheterization in 20 patients with pulmonary hypertension of various etiologies (Leuchte et al., European Respiratory Journal 2008;32(5):1289-95, PMID 18978135). Each patient received a single 100 microgram aviptadil inhalation. The result was small, transient, selective pulmonary vasodilation, with 6 of 20 patients experiencing greater than 20 percent reduction in pulmonary vascular resistance. The effect was smaller and more transient than an earlier open-label trial by Petkov in 2003 had suggested, where 8 patients with idiopathic PAH had shown more substantial acute and chronic responses to 50 microgram inhalations four times daily (Petkov et al., Journal of Clinical Investigation 2003;111(9):1339-46, PMID 12727925).

No subsequent Phase 3 of inhaled VIP for PAH has been completed. The orphan designation from 2005 remains.

Sarcoidosis: Prasse 2010

Prasse and colleagues conducted an open-label Phase II of nebulized VIP for pulmonary sarcoidosis in 20 patients over 4 weeks (American Journal of Respiratory and Critical Care Medicine 2010;182(4):540-8, PMID 20442436). The treatment was well tolerated. It reduced TNF-alpha in bronchoalveolar lavage fluid and expanded CD4+CD25+FoxP3+ regulatory T cells in peripheral blood, providing biologic-marker confirmation of VIP’s immunoregulatory activity in human disease tissue. No randomized controlled trial has followed, but FDA orphan designation for inhaled aviptadil in sarcoidosis was granted to AdVita Lifescience on August 3, 2021.

Migraine Provocation: Pellesi 2021

VIP infusion triggers migraine attacks in migraine-susceptible patients. In a randomized double-blind placebo-controlled crossover study, 15 of 21 patients (71 percent) developed migraine after VIP infusion versus 1 of 21 (5 percent) after placebo, p less than 0.001 (Pellesi et al., JAMA Network Open 2021;4(8):e2118543, PMID 34357396). This is an adverse-effect trial rather than a treatment trial, but it is mechanistically important for two reasons. First, headache is a recognized side effect of IV and inhaled aviptadil regardless of migraine history. Second, anyone with a personal history of migraine should treat VIP exposure of any route as a known headache trigger.

CIRS and the Shoemaker 2013 Open-Label Case Series

The 2013 open-label case series by Shoemaker, House, and Ryan is the flagship publication for intranasal VIP in chronic inflammatory response syndrome. Twenty patients received 50 microgram compounded aviptadil nasal spray four times daily (200 micrograms per day) and were followed for several months. The report described improvements in VEGF, TGF-beta-1, MMP-9, C4a, ADH to osmolality ratio, MSH, and symptom inventory measures (Shoemaker, House, Ryan, Health (Irvine, Calif.) 2013;5(3):396-401, doi:10.4236/health.2013.53053). A 2017 follow-up paper documented the 2-spray titration ceiling (400 micrograms per day) used after one month if labs and symptoms have not normalized, and reported on grey matter volume changes on MRI.

The evidence-grade caveats matter and should be stated plainly. The 2013 paper was published in Health, a journal from Scientific Research Publishing, which is on Beall’s List of predatory open access publishers and is not indexed in PubMed or MEDLINE. The study had no placebo arm, no blinding, no independent adjudication, and was conducted at a single clinic. The 2017 follow-up paper was in Internal Medicine Review, also outside PubMed. The 2013 paper claimed a Phase 3 was “underway”; thirteen years later no such trial has been registered or published.

A reader’s view of the strength of this evidence depends partly on their view of the CIRS diagnostic framework itself. The American College of Occupational and Environmental Medicine (2002 and 2011 statements), the American Academy of Allergy Asthma and Immunology (2006 position statement), the Institute of Medicine 2004 report on Damp Indoor Spaces and Health, the American College of Medical Toxicology (2025 update), and the CDC have all published positions concluding that systemic illness from inhaled non-occupational mycotoxin exposure is not supported by current data. A defending peer-reviewed review (Dooley et al., Annals of Medicine and Surgery 2024, PMC11623837) concludes the Shoemaker Protocol is “the only treatment in the published literature documenting clinical efficacy” for CIRS. The Lippincott journal where Dooley was published was delisted from Scopus in 2023 and restored in 2024 amid quality controversies.

This guide does not adjudicate the framework. It states what is verifiable: the supportive evidence for intranasal VIP in CIRS is a single open-label case series of 20 patients, published in 2013 in a non-PubMed-indexed journal, with no controlled trial in the intervening thirteen years. Patients should make informed decisions with that context.

What Is Not in the Evidence Base

No double-blind placebo-controlled RCT of intranasal VIP for CIRS has been published. No completed Phase 3 of any VIP formulation for any indication exists. The TESICO Phase 3 was stopped for futility. No FDA-approved oral, intranasal, IV, or inhaled VIP product exists in the United States (Invicorp, UK-only, intracavernosal, for erectile dysfunction, is the only marketed product anywhere). No published trial of subcutaneous VIP in humans for any indication exists. SC self-administration in the research-peptide community has no clinical-trial reference point.

Dosing

The dosing landscape for VIP is fragmented by route and use community. Below is the verified set.

Intranasal (Shoemaker CIRS Protocol)

The compounded preparation is aviptadil nasal spray at 50 micrograms per spray. The starting dose is 1 spray (50 mcg) four times daily, alternating nostrils between administrations. Total starting dose is 200 micrograms per day. After one month, if symptoms or lab markers (TGF-beta-1, C4a, VEGF, MMP-9) have not normalized, the dose may be titrated to 2 sprays (100 mcg) four times daily, alternating nostrils. Total titrated dose is 400 micrograms per day.

The detail “alternating nostrils” is load-bearing. Some patient guides describe “1 spray each nostril 4 times daily,” which is twice the starting dose and matches the titration ceiling rather than the starting dose. The compounding pharmacy labeling convention (Strive Pharmacy is one canonical example) explicitly says alternating nostrils for the first month.

Mandatory monitoring per the Shoemaker protocol includes serum lipase before the first dose and monthly thereafter, with immediate discontinuation if lipase is elevated. The pancreatitis signal is real and is the single most clinically actionable safety item for intranasal VIP. Monthly TGF-beta-1, C4a, VEGF, and MMP-9 are used to guide titration. The first dose is ideally administered in office with pre and post lipase and TGF-beta-1 measurements.

Entry gates to step 12 (where VIP sits in the 12-step protocol) include passing the Visual Contrast Sensitivity test, completing environmental remediation to an ERMI score below 2, MARCoNS-negative nasal culture, normal baseline serum lipase, and completion of all 11 prior protocol steps. The full protocol typically takes 6 to 24 months before patients reach the VIP step.

Intravenous (Clinical Trial / Hospital Use)

The TESICO and Youssef protocol used three 12-hour IV infusions on three successive days at escalating doses of 50, 100, and 150 picomoles per kilogram per hour. At a 70 kg body weight that corresponds to approximately 12, 23, and 35 micrograms per hour at the three steps. The IV route is hospital-only and not a community or outpatient practice.

Inhaled / Nebulized

AVICOVID-2 (NCT04360096) used 100 micrograms ZYESAMI in 1 mL normal saline three times daily via FDA-cleared mesh nebulizer for 10 days. Petkov 2003 used 50 micrograms per inhalation four times daily (200 mcg per day) chronically. Leuchte 2008 used a single 100 microgram inhalation. Prasse 2010 used nebulized VIP for 4 weeks, with 100 mcg four times daily commonly cited as the dose.

Subcutaneous (Research-Peptide Community Practice)

No clinical-trial-validated SC dosing exists. SC VIP for self-administration is a community practice without published trial backing. Reported community ranges run 50 to 200 micrograms SC daily, divided once or twice. The bioavailability rationale is that SC delivery exposes VIP to systemic DPP-IV and neprilysin degradation comparably to bolus IV, so effects are short and the doses needed to drive cAMP responses are higher than for inhaled or intranasal delivery to local target tissue. Theoretical risks include systemic hypotension and GI symptoms following the TESICO IV pattern.

A reader considering SC VIP should understand that this route has the least supporting evidence of any administration form.

Intracavernosal (Invicorp, UK Only)

Aviptadil 25 micrograms plus phentolamine 2 milligrams, intracavernosal injection, approved in the UK for erectile dysfunction. Not the audience for this guide.

Reconstitution

VIP is supplied as a lyophilized powder by both research-peptide vendors and 503A compounding pharmacies. The reconstitution guidance below applies to research-grade vials. Compounded products from a pharmacy come pre-reconstituted at a specified concentration (commonly 500 mcg/mL for nasal sprays) and do not require user reconstitution.

Diluent

Bacteriostatic water for injection (0.9 percent benzyl alcohol) is the default for multi-use preparations. Sterile water for injection is acceptable for single-use only. Saline (0.9 percent) is acceptable but can affect peptide stability over weeks of storage.

Concentration Math

For a 5 mg vial reconstituted with 2 mL bacteriostatic water, concentration is 2500 mcg/mL, or 25 micrograms per 0.01 mL (1 unit on a U-100 insulin syringe). For SC dosing in the 50 to 200 mcg community range, most administrations fall between 2 and 8 units on a U-100 syringe at this concentration. For a 5 mg vial reconstituted with 1 mL, concentration is 5000 mcg/mL, or 50 micrograms per unit. For a 10 mg vial with 2 mL, concentration is 5000 mcg/mL, or 50 micrograms per unit. Use a calculator (see the Peptide Toolkit reconstitution tool) for vial sizes and target doses that do not match these examples.

For intranasal preparation, compounding pharmacies typically work at 500 mcg/mL, which yields 50 micrograms per 0.1 mL metered spray. Other documented concentrations include 5 mg/mL and 10 mg/mL for higher per-administration doses. A 12 mL bottle at 50 mcg/spray yields 120 sprays, approximately 30 days of four-times-daily dosing.

Storage and Inspection

Lyophilized powder, unreconstituted, is stable at 2 to 8 degrees C for the labeled shelf life. Longer-term storage at -20 degrees C is preferred for vials not opened within 30 days. Reconstituted product with bacteriostatic water is stable at 2 to 8 degrees C for approximately 28 days; the benzyl alcohol provides bacteriostatic protection. Reconstituted product with sterile water (no preservative) is single-use within 24 hours. Avoid freeze-thaw cycles of reconstituted product. The reconstituted solution should be clear, colorless, and free of particulate matter; discard if cloudy, discolored, or particulate is visible.

Safety

VIP is generally well tolerated when delivered to target tissue (inhaled to airway, intranasal to nasal mucosa, intracavernosal to erectile tissue). Systemic IV delivery at therapeutic doses produces predictable, dose-related vasodilator and gastrointestinal side effects. The systemic risks are real and the trial data quantify them.

Cardiovascular

Hypotension is a direct vasodilator effect and the most common systemic adverse event. In TESICO IV aviptadil, hypotension occurred in 58.4 percent of aviptadil patients versus 41.3 percent of placebo patients (p less than 0.001). Tachycardia, both reflex and direct chronotropic, occurred in 9.5 percent versus 4.8 percent (p = 0.049). Flushing from cutaneous vasodilation is common with IV. Headache is common with IV and inhaled routes; VIP is a recognized experimental migraine trigger with 71 percent of migraine-susceptible patients developing migraine after IV exposure versus 5 percent on placebo (Pellesi 2021). In healthy volunteers receiving 400 picomoles per kilogram per hour IV, mean arterial pressure dropped approximately 12 percent and total peripheral resistance fell approximately 30 percent (Frase et al., 1987).

Gastrointestinal

Diarrhea is the second prominent systemic toxicity. VIP directly drives intestinal water and electrolyte secretion via VPAC1 and VPAC2 cAMP signaling. In TESICO IV, diarrhea occurred in 39.8 percent of aviptadil patients versus 11.3 percent of placebo (p less than 0.001), a 3.5-fold elevation. The mechanism is the same one that drives Verner-Morrison syndrome (watery diarrhea, hypokalemia, achlorhydria) in patients with VIPomas, where pancreatic VIP-secreting tumors drive serum VIP above 250 pg/mL and stool volumes exceed 700 mL per day fasting and 3 liters per day in 70 percent of patients. Abdominal cramping at higher doses and inhibition of gastric acid secretion are also documented.

Pancreatitis (Intranasal-Specific Monitoring Requirement)

The Shoemaker CIRS protocol requires monthly serum lipase monitoring with immediate discontinuation if lipase is elevated. Elevated lipase has been reported in the Shoemaker open-label series and follow-up papers. The mechanistic plausibility is that VIP is endogenously expressed in pancreas and VPAC1 and VPAC2 activation can stimulate pancreatic secretion; whether intranasal VIP at 200 to 400 micrograms per day produces enough systemic exposure to drive pancreatic effects is not formally characterized. Regardless, this is the most clinically actionable safety signal for intranasal VIP and a reader using this route should ensure lipase monitoring is in place before starting.

Other Reported Adverse Effects

Low blood pressure beyond the expected mild flush, stomachache, rash, and sporadic reports of dysphoria or depression have been described in Shoemaker patient communications. None are formally characterized in the published literature.

“Herxheimer” Framing

The Shoemaker community describes transient symptom worsening during the initial weeks of intranasal VIP as a Herxheimer reaction. There is no mechanistic basis for a classical Jarisch-Herxheimer reaction (a spirochete endotoxin die-off phenomenon classically seen in syphilis, Lyme, leptospirosis treatment) in the context of an immunomodulatory peptide. The empirical observation that some patients report initial symptom worsening is real; the “Herxheimer” label is community framing rather than peer-reviewed mechanism.

Pregnancy

No human pregnancy safety data exists. Aviptadil is not FDA-approved and has no formal pregnancy category. VIP relaxes uterine smooth muscle (Ottesen et al., European Journal of Clinical Investigation 1983;13(4):321-4, PMID 6413218); the theoretical concerns are placental vascular regulation, immune tolerance at the maternal-fetal interface where VIP plays a physiological role, and the absence of any human safety data. Standard practice is to avoid VIP in pregnancy.

Anaphylaxis and Long-Term Safety

No published case reports of anaphylaxis attributable to VIP or aviptadil were located. Class-effect plausibility for an endogenous peptide is low. Long-term safety data do not exist for any route; the 2013 Shoemaker case series followed patients for months, and the COVID trials dosed for less than 10 days. Chronic multi-year exposure data are absent.

Drug Interactions

All VIP drug interactions are theoretical or class-effect; no controlled clinical interaction studies exist. See also the Peptide Toolkit /peptide-interactions/ reference for the standardized interaction matrix.

The highest practical concern is additive hypotension. Nitrates (nitroglycerin, isosorbide), PDE5 inhibitors (sildenafil, tadalafil, vardenafil), alpha-blockers (tamsulosin, doxazosin), hydralazine, and antihypertensives in general (ACE inhibitors, ARBs, calcium channel blockers, diuretics, beta-blockers) all carry additive blood pressure reduction risk. TESICO documented 58 percent hypotension with IV aviptadil monotherapy; co-administration with another vasodilator would amplify the effect.

Sympathomimetic antagonism runs the other direction. Epinephrine, norepinephrine, phenylephrine, and pseudoephedrine counteract VIP vasodilation pharmacodynamically. For intranasal users, pseudoephedrine for nasal congestion would partially blunt the local effect of intranasal VIP.

cAMP potentiation is theoretical. PDE inhibitors (theophylline, caffeine, pentoxifylline) could amplify VIP’s cAMP-mediated effects. Sildenafil and tadalafil have minor PDE3 cross-activity, which overlaps with the hypotension concern.

No CYP interactions are expected. VIP is a peptide degraded by DPP-IV, neprilysin, and generic peptidases; it is not a CYP substrate, inducer, or inhibitor.

DPP-IV inhibitors (sitagliptin, vildagliptin, linagliptin, saxagliptin, the gliptin class for type 2 diabetes) inhibit the enzyme that degrades VIP. Theoretically, co-administration could prolong VIP exposure and amplify both intended and unintended effects. No clinical study of this interaction has been published. Worth flagging for prescribers managing diabetic patients who are also prescribed VIP nasal spray.

Regulatory Status (as of 2026-06-21)

VIP Product and Route Landscape

VIP reaches users through three distinct supply chains with very different regulatory framing. The molecule is the same in all three channels (synthetic 28-amino-acid VIP acetate); what differs is the manufacturing oversight, the labeling, and the legal pathway by which the product can be administered to a person.

ChannelForm / BrandRegulatory Status (US)Typical Use Case
Drug-product aviptadilRLF-100 (Relief Therapeutics) / ZYESAMI (NRx Pharmaceuticals); synthetic VIP acetate to API standardsNot FDA-approved. Investigational only. Three orphan designations (ARDS 2001, PAH 2005, sarcoidosis 2021-08-03). Two COVID-19 EUA applications declined (Nov 2021, Ju

Get peptide updates

Monthly peptide updates and FDA alerts. No spam, unsubscribe anytime.

Cycle Lengths

Cycling summary: No established cycling protocol for this peptide in the published literature. Community protocols vary; consult a compounding-focused clinician for a personalized plan.

Cycle timing should be informed by the peptide’s half-life, receptor tachyphylaxis profile (if applicable), and personal response monitored through lab work. Log both on-cycle and off-cycle biomarkers to understand recovery kinetics.

Lab Monitoring

Vip is a research-tier healing peptide with no established peripheral efficacy biomarker. Lab monitoring should be prudent general-health surveillance rather than efficacy tracking. The panels below cover organ systems most relevant during peptide research use.

Baseline (before starting): CBC with differential, comprehensive metabolic panel (CMP) covering LFTs and renal function, fasting lipid panel, hs-CRP for inflammatory baseline, fasting glucose, and HbA1c if metabolic risk factors are present. Age-appropriate cancer screening is prudent given rodent-only data on healing/angiogenic activity for most research peptides in this class.

During use: repeat CMP + CBC every 8-12 weeks. Repeat hs-CRP alongside if using for inflammatory conditions to track the inflammatory read against symptom response. Watch trends in ALT/AST (liver) and eGFR (renal) rather than single readings.

What to flag to a physician: injection-site erythema or nodule formation, unexplained weight changes, new joint or mass symptoms, any lab value trending outside reference range across two consecutive draws.

For the full class-wide monitoring framework and a plain-language comparison of DTC lab services for peptide users, see the Peptide Lab Testing pillar guide.

Storage & Travel

Storage

Lyophilized powder: Lyophilized powder freezer -20°C (-4°F) for long-term storage; stable at room temperature for shipping and short-term handling.

Reconstituted: Refrigerate reconstituted vial at 2-8°C (36-46°F); use within ~28 days per USP <797> peptide stability guidance. Never freeze a reconstituted vial, since freeze-thaw cycles damage peptide bonds and reduce potency.

Travel

Domestic flights: pack reconstituted vials in an insulated cooler with reusable ice packs. The TSA 3-1-1 rule limits liquids to 100 mL per container in carry-on; a 3-5 mL peptide vial passes with room to spare. Keep pharmacy or vendor documentation visible for TSA questions. Lyophilized powder in original sealed vial does not require cooling for short trips.

International travel: Vip is a research peptide in most jurisdictions with varying import restrictions — check the destination country’s rules before travel. Carry a physician’s letter if the peptide was prescribed by a compounding-focused clinician.

Road trips: keep the cooler in the cabin, not the trunk, during summer. Hotel mini-fridges vary in temperature stability; an insulated bag inside the mini-fridge adds a buffer.

Emergency out-of-fridge: reconstituted Vip at room temperature under 24 hours is generally still viable per USP stability guidance. Longer excursions or temperatures above 30°C compromise potency; discard and reconstitute a fresh vial.

Similar Posts